Flotufolastat F 18

DRUG3 trials

Sponsors

Novartis Pharmaceuticals, Urology Clinics of North Texas, University of Florida

Conditions

ProstateProstate Cancer

Early Phase 1

Pilot Study: Androgen Deprivation Therapy Impact on PSMA-PET Sensitivity in Prostatectomy Staging

CompletedNCT07069465

Urology Clinics of North TexasProstate Cancer

Start: 2024-06-15End: 2024-11-06Updated: 2025-07-16

Phase 1

Study to Assess [177Lu]Lu-PSMA-R2 (AAA602) and [225Ac]Ac-PSMA-R2 (AAA802) in Participants With PSMA-positive HRLPC

WithdrawnNCT06881823

Novartis PharmaceuticalsProstate Cancer

Start: 2026-06-29End: 2033-06-01Updated: 2025-12-29

Phase 2

POSLUMA® (18F-rhPSMA-7.3) PET-CT for PIRADS 2/3 Lesions

Active, not recruitingNCT07220720

University of FloridaProstate

Start: 2025-11-04End: 2032-11-15Target: 30Updated: 2025-11-06